An Indian government panel has recommended that Johnson & Johnson (J&J) pay compensation of at least US$28,500 to each Indian patient who suffered from artificial hip implants the US healthcare firm recalled eight years ago.
The Articular Surface Replacement (ASR) implants were recalled in 2010, after data suggested that they failed at a higher-than-expected rate.
In 2013, the firm agreed to pay nearly US$2.5 billion to settle thousands of lawsuits from those in the US who said they were injured by the implants.
In India, J&J paid US$2 million to patients for repeat surgeries and about US$250,000 in related diagnostic costs under its ASR reimbursement program, but the panel criticized the firm for offering no compensation.
“The fact remains that no compensation ever has been made by the firm in India to any patient,” the panel said in a 118-page report released late on Tuesday.
The panel was set up by the Indian Ministry of Health and Family Welfare, which has said it is reviewing the report.
J&J said its unit did not have access to data on patients who received implants because of patient confidentiality regulations, but it had given “top priority” to supporting ASR patients.
“The company has always put the health and safety of ASR patients first in everything we do,” it said in a statement.
About 93,000 people worldwide received ASR implants, the panel said, about 4,700 of them in India.
Metal hip implant systems such as ASR were designed to be more durable than a traditional metal-on-plastic ball-and-socket design, but many Indian patients experienced adverse reactions from the implant, the panel said.
It also criticized J&J for being “evasive” in sharing information on ASR’s design with it. Only in 2015, five years after the ASR recall, did the company run newspaper notices in India about the move.
This “shows the negligent behavior of the firm to reach out to the affected patients,” it said, calling for periodic ads to raise patient awareness about the implants.
J&J denied the panel’s assessment, saying its unit had not been evasive and had “fully cooperated with the expert committee in their investigation.”
The panel findings, first reported by Indian media last week, have sparked a public relations crisis for the US-based company, which has also faced criticism from patient rights activists.
J&J “has the responsibility to track patients, make them aware of the adverse effects and compensate them,” said Oommen Kurian, a health researcher at the New Delhi-based Observer Research Foundation.
RUN IT BACK: A succesful first project working with hyperscalers to design chips encouraged MediaTek to start a second project, aiming to hit stride in 2028 MediaTek Inc (聯發科), the world’s biggest smartphone chip supplier, yesterday said it is engaging a second hyperscaler to help design artificial intelligence (AI) accelerators used in data centers following a similar project expected to generate revenue streams soon. The first AI accelerator project is to bring in US$1 billion revenue next year and several billion US dollars more in 2027, MediaTek chief executive officer Rick Tsai (蔡力行) told a virtual investor conference yesterday. The second AI accelerator project is expected to contribute to revenue beginning in 2028, Tsai said. MediaTek yesterday raised its revenue forecast for the global AI accelerator used
TEMPORARY TRUCE: China has made concessions to ease rare earth trade controls, among others, while Washington holds fire on a 100% tariff on all Chinese goods China is effectively suspending implementation of additional export controls on rare earth metals and terminating investigations targeting US companies in the semiconductor supply chain, the White House announced. The White House on Saturday issued a fact sheet outlining some details of the trade pact agreed to earlier in the week by US President Donald Trump and Chinese President Xi Jinping (習近平) that aimed to ease tensions between the world’s two largest economies. Under the deal, China is to issue general licenses valid for exports of rare earths, gallium, germanium, antimony and graphite “for the benefit of US end users and their suppliers
Dutch chipmaker Nexperia BV’s China unit yesterday said that it had established sufficient inventories of finished goods and works-in-progress, and that its supply chain remained secure and stable after its parent halted wafer supplies. The Dutch company suspended supplies of wafers to its Chinese assembly plant a week ago, calling it “a direct consequence of the local management’s recent failure to comply with the agreed contractual payment terms,” Reuters reported on Friday last week. Its China unit called Nexperia’s suspension “unilateral” and “extremely irresponsible,” adding that the Dutch parent’s claim about contractual payment was “misleading and highly deceptive,” according to a statement
The Chinese government has issued guidance requiring new data center projects that have received any state funds to only use domestically made artificial intelligence (AI) chips, two sources familiar with the matter told Reuters. In recent weeks, Chinese regulatory authorities have ordered such data centers that are less than 30 percent complete to remove all installed foreign chips, or cancel plans to purchase them, while projects in a more advanced stage would be decided on a case-by-case basis, the sources said. The move could represent one of China’s most aggressive steps yet to eliminate foreign technology from its critical infrastructure amid a
RSS